Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.66
(
-1.98%
)
Bitcoin
74,261.61
(
0.43%
)
News Focus
News Focus
Post# of 446786
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ProLiberty

Send PM Follow Ignore
Followers 5
Posts 509
Boards Moderated 0
Alias Born 06/11/2024

ProLiberty

Re: JRoon71 post# 441131

Friday, 11/14/2025 2:13:47 PM

Friday, November 14, 2025 2:13:47 PM

Post# of 446786
Makes no sense. Generic got approval in June 2024... Vascepa gets same CVRR approval a month later in July 2024? Again... scrap deal and don't pay out $15m... zero value in branded with generic already approved. Where is the 6 year exclusivity for the one that beat Vascepa to the CVRR approval punch?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News
InvestorsHub NewsWire

ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM

Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM

Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM

DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM

Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM

Start posting your company's news
Only $200 per official company press release!